argenx halts Phase 3 efgartigimod Sjögren’s trial after futility analysis
argenx stops the Phase 3 UNITY efgartigimod trial in Sjögren’s disease for futility despite earlier positive Phase 2 results.
Pharma & Biotech
Features & Analysis
Why destroying IgG faster can treat myasthenia gravis without depleting B cells
FcRn normally rescues IgG antibodies from intracellular destruction and returns them to circulation. Blocking that recycling pathway accelerates IgG clearance, including pathogenic autoantibodies, without directly eliminating the B cells that produced them.
Pharma & Biotech
Why TG Therapeutics’ BRIUMVI data could open a new treatment path in myasthenia gravis
Find out how TG Therapeutics’ BRIUMVI data could shape a new maintenance strategy in myasthenia gravis treatment.